<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AimsPatients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) show impaired health-related quality of life (HRQoL), an important target for therapeutic intervention </plain></SENT>
<SENT sid="1" pm="."><plain>Impaired iron homeostasis may be one mechanism underlying the poor physical condition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>This detailed subanalysis of the previously published FAIR-HF study evaluated baseline HRQoL in iron-deficient patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> and the effect of intravenous ferric carboxymaltose (FCM) on HRQoL.Methods and resultsFAIR-HF randomized 459 patients with reduced left ventricular ejection fraction and <z:e sem="disease" ids="C0240066" disease_type="Disease or Syndrome" abbrv="">iron deficiency</z:e>, with or without <z:hpo ids='HP_0001903'>anaemia</z:hpo>, to FCM or placebo (2:1) </plain></SENT>
<SENT sid="3" pm="."><plain>Health-related quality of life was assessed at baseline and after 4, 12, and 24 weeks of therapy using the generic EQ-5D questionnaire and disease-specific Kansas City <z:hpo ids='HP_0001638'>Cardiomyopathy</z:hpo> Questionnaire (KCCQ) </plain></SENT>
<SENT sid="4" pm="."><plain>Baseline mean Visual Analogue Scale (VAS) score was 54.3 ± 16.4 and KCCQ overall summary score was 52.4 ± 18.8 </plain></SENT>
<SENT sid="5" pm="."><plain>Ferric carboxymaltose significantly improved VAS and KCCQ (mean differences from baseline in KCCQ overall, clinical and total symptom scores, P&lt; 0.001 vs. placebo) at <z:hpo ids='HP_0000001'>all</z:hpo> time points </plain></SENT>
<SENT sid="6" pm="."><plain>At Week 24, significant improvement vs. placebo was observed in four of the five EQ-5D dimensions: mobility (P= 0.004), self-care (P&lt; 0.001), pain/discomfort (P= 0.006), <z:hpo ids='HP_0000739'>anxiety</z:hpo>/<z:hpo ids='HP_0000716'>depression</z:hpo> (P= 0.012), and usual activity (P= 0.035) </plain></SENT>
<SENT sid="7" pm="."><plain>Ferric carboxymaltose improved <z:hpo ids='HP_0000001'>all</z:hpo> KCCQ domain mean scores from Week 4 onward (P≤ 0.05), except for self-efficacy and social limitation </plain></SENT>
<SENT sid="8" pm="."><plain>Effects were present in both anaemic and non-anaemic patients.ConclusionsHRQoL is impaired in iron-deficient patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Intravenous FCM significantly improved HRQoL after 4 weeks, and throughout the remaining study period </plain></SENT>
<SENT sid="10" pm="."><plain>The positive effects of FCM were independent of <z:hpo ids='HP_0001903'>anaemia</z:hpo> status </plain></SENT>
</text></document>